Form 4: GRI Bio CEO Acquires 129,730 Stock Options

GRI Bio's CEO, Walter Marc Hertz, acquired 129,730 stock options at an exercise price of $0.6857 on January 23, 2025.

Summary

• Walter Marc Hertz, the CEO of GRI Bio, Inc., has acquired 129,730 stock options.
• The options were granted on January 23, 2025, and have an exercise price of $0.6857 per share.
• The options become exercisable on January 23, 2025, and expire on January 23, 2035.
• The underlying security for these options is 129,730 shares of GRI Bio's common stock.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is neither particularly positive nor negative. It is a standard part of executive compensation.

Positives

• The acquisition of stock options by the CEO could indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, similar to companies like Amgen, Gilead, and Regeneron.
• The exercise price and vesting schedule are typical for such grants, aligning with industry practices for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the CEO's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, executive compensation, GRI Bio, Walter Marc Hertz